kabutan

JCR Pharma, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 83%

Wed Jan 28, 2026 5:00 pm JST Earnings

4552 JCR Pharmaceuticals Co.,Ltd. 【J-GAAP】

Earnings Report

JCR Pharmaceuticals Co.,Ltd. <4552> [TSE Prime] announced its financial results after the market closed on January 28th (17:00). The consolidated ordinary profit/loss for the cumulative third quarter of the fiscal year ending March 2026 (April to December) turned into a profit of 0.71 billion yen (compared to a loss of 1.38 billion yen in the same period last year).

However, the full-year forecast for consolidated ordinary profit has decreased 83.3%, from the previous forecast of 2.40 billion yen to 0.40 billion yen (compared to a loss of 7.47 billion yen in the previous period).

Based on the full-year plan announced by the company after the downward revision, our estimate of the consolidated ordinary profit/loss for the October to March period (second half) has been revised downward from an expected profit of 0.03 billion yen to a loss of 1.96 billion yen (compared to a loss of 5.85 billion yen in the same period of the previous year), turning to a loss outlook.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit/loss turned to a loss of 1.65 billion yen (compared to a profit of 0.24 billion yen in the same period last year). The operating profit/loss margin drastically worsened from -0.2% in the same period last year to -21.7%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 33,718 7,809 7,388 5,160 41.4 101.7 Jan 26, 2024 J-GAAP
Apr - Dec, 2024 25,880 -754 -1,380 -576 -4.6 ー Jan 31, 2025 J-GAAP
Apr - Dec, 2025 30,353 427 711 1,744 14.3 177.8 Jan 28, 2026 J-GAAP
YoY +17.3% － － － －

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2025 Prev 16,438 221 38 1,290 10.6 10 Oct 30, 2025 J-GAAP
Oct - Mar, 2025 New 18,138 -1,979 -1,962 -110 -0.9 10 Jan 28, 2026 J-GAAP
Revision Rate +10.3% － － － －

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 37,800 2,600 2,400 3,000 24.6 20 May 13, 2025 J-GAAP
Mar, 2026 New 39,500 400 400 1,600 13.1 20 Jan 28, 2026 J-GAAP
Revision Rate +4.5% -84.6% -83.3% -46.7% -46.6%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 16,415 -5,911 -5,856 -4,068 -32.9 10 May 13, 2025 J-GAAP
Oct - Mar, 2025 Guidance 18,138 -1,979 -1,962 -110 -0.9 10 Jan 28, 2026 J-GAAP
YoY +10.5% +66.5% +66.5% +97.3% +97.3%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 42,871 7,531 7,264 5,507 44.1 20 May 10, 2024 J-GAAP
Mar, 2025 33,072 -6,650 -7,477 -4,759 -38.4 20 May 13, 2025 J-GAAP
Mar, 2026 Guidance 39,500 400 400 1,600 13.1 20 Jan 28, 2026 J-GAAP
YoY +19.4% － － － －

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 9,223 -15 241 115 0.9 -0.2 Jan 31, 2025 J-GAAP
Jan - Mar, 2025 7,192 -5,896 -6,097 -4,183 -33.8 -82.0 May 13, 2025 J-GAAP
Apr - Jun, 2025 8,569 -606 -749 -546 -4.5 -7.1 Jul 30, 2025 J-GAAP
Jul - Sep, 2025 12,793 2,985 3,111 2,256 18.5 23.3 Oct 30, 2025 J-GAAP
Oct - Dec, 2025 8,991 -1,952 -1,651 34 0.3 -21.7 Jan 28, 2026 J-GAAP
YoY -2.5% -12,913.3% － -70.4% -69.6%

Related Articles